Urushiol Ester Desensitization for Poison Ivy Dermatitis

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current treatments for poison ivy and oak dermatitis are inadequate, with commercial barrier products offering limited protection and desensitization regimens being unreliable and causing side effects, while existing pharmaceutical formulations fail to provide durable hyposensitization against urushiol allergens.

Innovation Solution

A pharmaceutical composition using urushiol esters in sesame seed oil with benzyl alcohol and ethyl alcohol, specifically formulated to be administered parenterally, which quickly hydrolyze to generate active urushiol that binds to cell membranes, providing effective desensitization against contact dermatitis caused by Anacardiaceae and Ginkgoaceae allergens.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If commercial barrier products are used to prevent urushiol contact, then some protection is offered, but the protection is limited and not reliable

Engineering Contradiction:
Improveprotection effectivenessVSAvoidurushiol penetration
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent transforms urushiol from its harmful free base form into stable ester derivatives that cannot penetrate the skin. By changing the chemical parameter of urushiol through esterification, the composition maintains the allergenic structure needed for desensitization while eliminating the harmful penetrating property, resolving the contradiction between reliability of protection and harmful factor prevention

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The esterified urushiol derivatives act as an intermediary substance that mimics the allergen structure without possessing its harmful penetrating capabilities. This intermediary provides the immunological stimulus needed for desensitization while being safe for parenteral administration, addressing both the need for reliable protection and the elimination of harmful effects

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If desensitization regimens using urushiol extracts are administered, then hyposensitization is attempted, but the results are unreliable and side effects occur

Engineering Contradiction:
Improvedesensitization effectivenessVSAvoidside effects
Core Design Contradiction:
ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent changes the chemical state of urushiol from free base to ester derivatives, fundamentally altering its properties. This parameter change enables reliable desensitization by providing consistent immunological stimulation without the unpredictable side effects associated with traditional urushiol extract regimens, as the esterified form is safer for parenteral administration

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The esterified urushiol derivatives function as controlled, temporary immunological stimuli that achieve desensitization without causing persistent harmful effects. The composition provides sufficient antigenic material for hyposensitization while the ester structure ensures it degrades or is metabolized safely, eliminating the need for long-term management of side effects

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

3Duration of action of stationary object

If existing pharmaceutical formulations are used, then treatment is provided, but durable hyposensitization is not achieved

Engineering Contradiction:
Improvehyposensitization durationVSAvoidprophylactic effectiveness
Core Design Contradiction:
Duration of action of stationary objectVSReliability

Solution Approach 1:

By esterifying urushiol, the patent creates a stable derivative that provides prolonged immunological protection. The ester structure allows for sustained release and metabolism, achieving durable hyposensitization that lasts through the metabolism of the parenteral formulation, thus resolving the contradiction between duration of action and reliability of prophylaxis

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The composition effectively desensitizes subjects by administering urushiol esters, offering significant protection against urushiol challenges, as demonstrated in guinea pig models, with prolonged hyposensitization and reduced skin lesion scores, indicating improved safety and efficacy compared to existing treatments.

Implementation Method 1

urushiol esters...which quickly hydrolyze to generate active urushiol that binds to cell membranes

Methodology Applied
Scientific EffectHydrolysis: Hydrolysis

Data Source

PatentEP3274322B1Stable compositions for prevention / prophylactic treatment of poison ivy dermatitis
Publication Date: 2024.08.14 UNIVERSITY OF MISSISSIPPI
  • EP3274322B1 patent drawingFigure 1A~1C
  • EP3274322B1 patent drawingFigure 2A~2C
  • EP3274322B1 patent drawingFigure 3A~3C

AI summary

The present invention, in one or more embodiments, comprises derivatives of 3-n-pentadecylcatechol (poison ivy urushiol saturated congener) and/or 3 -n-heptadecyl catechol (poison oak urushiol saturated congener) as compositions for the prevention and/or prophylactic treatment of contact dermatitis caused by poison ivy and poison oak. The present invention is also directed towards processes for making such compounds. Disclosed are compounds which are effective for tolerizing and desensitizing a subject against allergens contained in plants of the Anacardiaceae and Ginkgoaceae families comprising urushiol esters of general formula (IA) [Formula should be entered here] tolerizing and desensitizing mammals, including humans, to allergens contained in plants of the Anacardiaceae and Ginkgoaceae families is attained by administering a formulation containing at least one urushiol ester compound.